prikaz prve stranice dokumenta Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART
  Download
PDF 159.07 KB
Scientific paper - Original scientific paper
Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART
Collegium Antropologicum, 30 (2006), Suppl.; 33-38. urn:nbn:hr:105:092867
Židovec Lepej, Snježana; Kosor, Ela; Gagro, Alenka; Vince, Adriana; Remenar, Anica; Poljak, Mario

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Židovec Lepej, S., Kosor, E., Gagro, A., Vince, A., Remenar, A. & Poljak, M. (2006). Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART. Collegium Antropologicum, 30. (Suppl.), 33-38. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:092867

Židovec Lepej, Snježana, et al. "Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART." Collegium Antropologicum, vol. 30, no. Suppl., 2006, pp. 33-38. https://urn.nsk.hr/urn:nbn:hr:105:092867

Židovec Lepej, Snježana, Ela Kosor, Alenka Gagro, Adriana Vince, Anica Remenar and Mario Poljak. "Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART." Collegium Antropologicum 30, no. Suppl. (2006): 33-38. https://urn.nsk.hr/urn:nbn:hr:105:092867

Židovec Lepej, S., et al. (2006) 'Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART', Collegium Antropologicum, 30(Suppl.), pp. 33-38. Available at: https://urn.nsk.hr/urn:nbn:hr:105:092867 (Accessed 26 November 2024)

Židovec Lepej S, Kosor E, Gagro A, Vince A, Remenar A, Poljak M. Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART. Collegium Antropologicum [Internet]. 2006 December [cited 2024 November 26];30(Suppl.):33-38. Available at: https://urn.nsk.hr/urn:nbn:hr:105:092867

S. Židovec Lepej, E. Kosor, A. Gagro, A. Vince, A. Remenar and M. Poljak, "Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART", Collegium Antropologicum, vol. 30, no. Suppl., pp. 33-38, December 2006. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:092867. [Accessed: 26 November 2024]

Metadata
Title (english)Persistant immunodominant anti-gag SLYNTVATL responses in HIV-patients with up to 7 years of HAART
AuthorSnježana Židovec Lepej
AuthorEla Kosor
AuthorAlenka Gagro
AuthorAdriana Vince
AuthorAnica Remenar
AuthorMario Poljak
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
We analyzed Gag-specific CD8+ T-cells in HIV-patients on long-term HAART and in untreated chronically-infected patients by using iTAg MHC class I tetramers (HLA-A*0201) specific for SLYNTVATL. Gag SLYNTVATL-specific CD8+ T-cells were detectable in 18 of 26 treated patients (median 5.2 years of HAART) and in 10 of 14 untreated patients. Median percentage of Gag SLYNTVATL-specific CD8+ T-cells in treated patients was 0.10 (range 0.00-0.70%). Median number of Gag SLYNTVATL-specific CD8+ T-cells per 50,000 CD8+ T-cells was 56.0 cells (range 2.0-344.0 cells) and was not significantly different compared with untreated patients (p = 0.978). Numbers of Gag SLYNTVATL-specific CD8+ T-cells were inversely correlated with the duration of undetectable plasma viremia (p = 0.02, Rho = -0.430). Chronically-infected HIV-patients on HAART (for up to 7.7 years) maintained a stable subpopulation of Gag SLYNTVATL-specific CD8+ T-cells. This finding is relevant for the analysis of treatment-induced immune reconstitution and, possibly, for future therapeutic strategies in HIV-disease.
Abstract (croatian)
U ovom smo istraživanju analizirali Gag-specifične CD8+ T-limfocite u HIV-bolesnika liječenih HAART-om kao i u neliječenih zaraženih osoba primjenom iTAg MHC tetramera klase 1 (HLA-A*0201) specifičnih za SLYNTVATL. Gag SLYNTVATL-specifične CD8+ T-limfocite dokazali smo u 18 od 26 liječenih bolesnika (medijan 5,2 godine HAART-a) i u 10 od 14 neliječenih pacijenata. Medijan postotka Gag SLYNTVATL-specifičnih CD8+ T-limfocita u liječenih bolesnika bio je 0,10 (raspon 0,00–0,70%). Medijan broja Gag SLYNTVATL-specifičnih CD8+ T-limfocita na 50.000 CD8+ T-limfocita bio je 56,0 stanica (raspon 2,0–344,0 stanica) i nije bio značajno različit u odnosu na neliječene zaražene osobe (p=0,978). Broj Gag SLYNTVATL-specifičnih CD8+ T-limfocita negativno je korelirao s dužinom perioda nemjerljive viremije u plazmi (p=0,02, Rho= –0,430). U liječenih HIV-bolesnika (do 7,7 godina HAART-a) postoji stabilna populacija Gag SLYNTVATL specifičnih CD8+ T-limfocita. Rezultati ovog rada značajni su za analizu liječenjem-potaknute imunološke rekonstitucije te za razvoj novih strategija liječenja u HIV-bolesti.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCollegium Antropologicum
Numberingvol. 30, no. Suppl., pp. 33-38
p-ISSN0350-6134
URN:NBNurn:nbn:hr:105:092867
Publication2006-12
Document URLhttps://hrcak.srce.hr/27716
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 11:01:17